NCT05664334 - Safety and Immunogenicity of IVX-A12 in Healthy Older Adults | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

September 21, 2022

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions

Healthy

Interventions

BIOLOGICAL

IVX-121

75 mcg of IVX-121 without MF59®

BIOLOGICAL

IVX-241

75 mcg of IVX-241 without MF59®

BIOLOGICAL

Placebo

Diluent

BIOLOGICAL

IVX-121

75 mcg of IVX-121, without MF59®

BIOLOGICAL

IVX-241

150 mcg IVX-241, without MF59®

BIOLOGICAL

IVX-241

225 mcg of IVX-241, without MF59®

BIOLOGICAL

IVX-121

75 mcg of IVX-121, with MF59®

BIOLOGICAL

IVX-241

75 mcg of IVX-241, with MF59®

BIOLOGICAL

IVX-241

150 mcg IVX-241, with MF59®

OTHER

MF59®

MF59® as an adjuvant

Trial Locations (4)

30331

CenExcel ACMR, Atlanta

33024

CenExcel RCA, Hollywood

68134

Meridien Clinical Research, Omaha

78520

PanAmerican Clinical Research, Brownsville